How Should a Startup Document Investor Default Remedies in a Multi-Close Bridge Financing?

In a multi-close bridge financing, investor default remedies must be defined in writing before the first close. The bridge agreement should specify the forfeiture of allocation rights, the reallocation of unfunded commitments to willing participants, the dilution treatment applied to defaulting investors, and the cure window available before any remedy takes effect. Without these provisions in place, one investor missing a close can freeze the round, create cap table ambiguity, and give defaulting investors leverage they have not earned.

This guide covers the specific provisions that belong in multi-close bridge documents, how each one protects the company and participating investors, and what happens to the cap table when a default goes undocumented. For founders already working through how a pay-to-play bridge handles investor participation penalties, this article is the operational companion focused on remedy drafting and close administration.

If your bridge documents include side letters, the default remedy framework must extend to those agreements as well. Side letters that modify participation rights or grant enhanced allocation access can create conflicting obligations when a close is missed. Review how quiet investor accommodations in side letters can surface as diligence problems before finalizing your bridge package.

Why Multi-Close Bridges Create Default Risk

A single-close bridge is simple. All investors fund on the same day. There is no gap between commitment and capital.

A multi-close bridge works differently. The company sets a target raise and opens a window, often 60 to 90 days, during which investors can fund at different times. The first close might bring in 60% of the target. The second and third closes fill the rest.

That structure creates a specific risk: an investor who commits to a later close may not fund when that close arrives. Their reasons vary. Market conditions shift. Their own liquidity changes. They decide the company is no longer the right fit. Whatever the cause, the result is the same. The company has built its operating plan around capital that has not arrived.

The Cap Table Problem When a Close Is Missed

When an investor misses a close without a documented remedy, the company faces three problems at once.

First, the unfunded commitment sits in a legal gray zone. The investor may argue they still have the right to fund on modified terms. The company may believe the commitment has lapsed. Without written remedies, both positions are defensible.

Second, the cap table cannot be finalized. Participating investors who funded earlier closes are waiting to see how much dilution they face from the later closes. If a later close is uncertain, the fully diluted cap table is uncertain.

Third, the round timeline extends. Every week spent resolving an undocumented default is a week the company is not closing its next equity round.

What Undocumented Defaults Cost

The cost is not just administrative. A founder who cannot enforce a funding commitment has lost negotiating leverage. The defaulting investor knows the company needs the capital. They can use that need to renegotiate terms, request governance accommodations, or simply delay without consequence.

Key insight: Default remedies are founder protection tools. They shift leverage back to the company by making the cost of non-performance clear before any investor signs.

The Core Default Remedy Provisions

Four remedy types belong in every multi-close bridge agreement. Each one addresses a different dimension of the default problem.

Forfeiture of Allocation Rights

This provision states that an investor who fails to fund by the scheduled close date forfeits their right to participate in that close and any subsequent closes. The forfeiture is automatic. It does not require a board vote or a separate notice to trigger.

Forfeiture is the foundation of the remedy framework. Without it, a defaulting investor retains their allocation and can claim it later, potentially at a time when the company would prefer to bring in a different investor.

Reallocation to Participating Investors

Once a commitment is forfeited, the bridge agreement should specify how the unfunded amount is reallocated. The two common approaches are:

• Pro-rata reallocation: The forfeited amount is offered to all participating investors in proportion to their existing commitments. An investor who funded 20% of the committed capital gets 20% of the reallocated amount.
• Board-directed reallocation: The board has discretion to allocate the forfeited amount to any participating investor or new investor it chooses. This approach gives the company more flexibility but requires a board resolution.

Pro-rata reallocation is simpler to administer and creates fewer grounds for dispute. Board-directed reallocation is more useful when the company wants to bring in a strategic new investor to fill the gap. For a detailed framework on allocation mechanics when bridge demand shifts, see how to allocate bridge financing when investor commitments exceed or fall short of the target raise.

Dilution Treatment for Defaulting Investors

Forfeiture removes the defaulting investor's future allocation rights. Dilution treatment addresses what happens to the equity they already hold.

In a standard forfeiture, the defaulting investor keeps their existing equity but receives no new instruments from the bridge. Their ownership percentage on a fully diluted basis decreases as the bridge instruments issued to participating investors convert into equity.

In a more aggressive structure, the bridge agreement can include a penalty dilution provision. This applies an additional dilution adjustment to the defaulting investor's existing holdings, beyond the natural dilution from the new instruments. Penalty dilution requires explicit drafting and is typically reserved for situations where the defaulting investor's commitment was material to the round's viability.

Cure Rights and Notice Windows

A cure right gives the defaulting investor a defined period to fund after missing the scheduled close date. The standard window is 5 to 10 business days after written notice from the company. During that window, the forfeiture and reallocation provisions are held in suspension.

Cure rights serve two purposes. They give good-faith investors a path to fix an administrative failure. They also protect the company from legal challenges by investors who claim they were not given adequate notice before remedies were applied. Standard convertible note financing filings show that cure periods following written notice of default are a routine and expected feature of institutional-grade bridge instruments.

The cure window should be short enough to keep the round timeline intact. A 5-business-day cure period with a 2-business-day notice requirement is a workable standard for most bridge structures. Longer windows create uncertainty for participating investors waiting on the final cap table.

Drafting note: The notice requirement and cure window must be defined with specific business-day counts, not general language like "promptly" or "within a reasonable time." Vague timing language is the most common source of default remedy disputes.

{{main_cta}}

How to Document Each Remedy in the Bridge Agreement and Side Letters

The remedy framework belongs in two places: the main bridge agreement and any side letters that modify individual investor terms.

In the Bridge Agreement

The note purchase agreement or stock purchase agreement is where the default remedy provisions live. Each provision should appear in its own defined section, not buried in a general representations clause.

The checklist below covers the minimum required provisions:

• Closing schedule: A defined date or date range for each anticipated close, with the maximum number of closes authorized by the board
• Funding deadline: The specific date and time by which each investor must wire funds for a given close. SEC-filed bridge note agreements consistently define failure to pay as a default trigger when the non-payment continues for five business days after written notice, making that window a market-standard reference point
• Default trigger: Language stating that failure to fund by the deadline constitutes a default, with no cure period required before the trigger activates
• Notice obligation: The company's obligation to deliver written notice of default to the investor within 2 business days of the missed funding deadline
• Cure window: The investor's right to cure by funding within 5 business days of receiving the default notice
• Forfeiture mechanics: Automatic forfeiture of allocation rights upon expiration of the cure window, with no further action required by the company
• Reallocation procedure: The method by which forfeited amounts are redistributed, including the timeline for offering the reallocation to eligible participants
• Dilution schedule: A table or formula showing the cap table impact of each close scenario, including the scenario where one or more investors default

In Side Letters

Side letters that grant enhanced pro-rata rights, modified participation thresholds, or deferred funding windows create exceptions to the standard remedy framework. Each exception must be reconciled with the main bridge agreement before the first close.

The most common conflict arises when a side letter grants an investor the right to fund at a later close without forfeiting their allocation. If the main agreement treats all missed deadlines as defaults, the side letter creates a carve-out that other investors may not know about. That asymmetry can become a dispute if the investor exercises the deferred funding right and other investors argue the allocation should have been reallocated.

The fix is straightforward. Any side letter that modifies the default remedy framework must cross-reference the specific provisions it overrides. The main agreement should also include a disclosure schedule listing all side letters that affect the remedy mechanics.

For bridge rounds where the minimum cash covenant structure also involves cure and standstill mechanics, the notice and cure windows in the default remedy framework should be coordinated with the cash covenant cure periods already in the bridge agreement to avoid conflicting timelines running simultaneously. If your reporting package is already too broad, clean that up before you layer in remedy language. How to push back on broad investor reporting clauses pre-close is the right companion read for that cleanup.

What Happens When the Framework Is in Place

A growth-stage software company structured a $12M multi-close bridge with four anticipated closes over 90 days. One investor, committed for $1.5M in the third close, failed to fund on the scheduled date. Because the bridge agreement included a 2-business-day notice obligation and a 5-business-day cure window, the company sent written notice the same week.

The investor did not cure. The forfeiture provision activated automatically. The $1.5M allocation was offered to the two largest participating investors on a pro-rata basis. Both accepted within four business days. The third close funded in full, one week behind the original schedule.

The cap table was updated to reflect the reallocation. The defaulting investor retained their existing equity from prior rounds but received no bridge instruments. Their fully diluted ownership decreased as the bridge notes converted in the subsequent priced round.

The round closed without litigation and without renegotiation. The outcome was possible because the remedy sequence was defined before any investor signed.

The lesson: Documented remedies do not prevent defaults. They determine what happens next. A company with a clear remedy framework resolves a default in days. A company without one resolves it in months, if at all.

IRC Partners works with growth-stage founders structuring institutional-grade bridge rounds from $5M to $250M. If your bridge documents do not yet include a default remedy framework, that gap should be closed before the first investor signs a commitment letter. The structure of the remedy sequence is where the round either holds together or starts to fracture.

Frequently Asked Questions

What is a default remedy provision in a multi-close bridge financing?

A default remedy provision is a clause in the bridge agreement that defines what happens when an investor fails to fund on the scheduled close date. It typically includes a written notice requirement, a cure window of 5 to 10 business days, automatic forfeiture of allocation rights if the investor does not cure, and a reallocation procedure for the unfunded amount. The provision must be in the agreement before the first close to be enforceable.

How long should the cure window be in a multi-close bridge default remedy?

A 5-business-day cure window, triggered by written notice from the company within 2 business days of the missed funding deadline, is a workable standard for most growth-stage bridge rounds. Shorter windows reduce the risk of round delays but may create grounds for legal challenge if an investor claims inadequate notice. Longer windows, beyond 10 business days, create uncertainty for participating investors waiting on the finalized cap table.

Does a defaulting investor lose their existing equity in the company?

A standard forfeiture provision removes the defaulting investor's right to participate in the current and future closes. It does not cancel the equity they already hold from prior rounds. Their existing shares remain intact. Their fully diluted ownership percentage decreases because the bridge instruments issued to participating investors convert into equity at the next priced round, diluting everyone who did not receive new instruments.

Can a side letter override the default remedy provisions in the main bridge agreement?

A side letter can modify the default remedy framework for a specific investor, but only if the modification is explicitly documented and cross-referenced in the main agreement. A side letter that grants deferred funding rights without disclosing that carve-out to other investors creates an asymmetry that can become a dispute. The main agreement should include a disclosure schedule listing all side letters that affect remedy mechanics. The same drafting discipline applies when investors ask for broader reporting access. Negotiate information rights before signing $10M+ deals shows how to narrow those rights before they harden.

What is the difference between forfeiture and penalty dilution in a bridge default?

Forfeiture removes the defaulting investor's right to receive new bridge instruments. Their existing equity is unaffected, but they do not participate in the upside of the bridge conversion. Penalty dilution goes further. It applies an additional dilution adjustment to the defaulting investor's existing holdings, beyond the natural dilution from the new instruments. Penalty dilution requires explicit drafting and is typically reserved for situations where the default was material to the round's viability.

What board actions are required when a bridge investor defaults?

The board does not need to vote to trigger forfeiture if the bridge agreement makes the forfeiture automatic upon expiration of the cure window. The board does need to act if the reallocation method is board-directed rather than pro-rata. In that case, a board resolution should document the basis for the reallocation decision, confirm that any conflicted directors recused themselves, and record the final allocation table before any new instruments are issued to replacement participants.

How should a company document the cap table after a bridge default and reallocation?

The company should update the cap table model to reflect three changes: the removal of the defaulting investor's expected bridge instruments, the addition of bridge instruments issued to the investors who absorbed the reallocated amount, and the revised fully diluted ownership percentages for all parties. The updated cap table should be approved by the board, confirmed with the company's securities counsel, and distributed to all participating investors before the next close proceeds.

Continue reading this series:

• How a startup should structure a pay-to-play bridge when preferred investors decline to participate
• When bridge financing should include a minimum cash covenant before the next equity round
• How side letters become Series B diligence landmines

By the time most founders are rehearsing the pitch, the outcome of the raise has already been set by the structure underneath it. IRC Partners advises operators raising $5M to $250M of institutional capital and accepts seven strategic partners per quarter. If you are going to market this year, have the structure reviewed before investors do. Schedule a call with our team here.